Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2003;34:e48-e50
Published online before print May 15, 2003, doi: 10.1161/01.STR.0000073788.81170.1C
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/6/e48    most recent
01.STR.0000073788.81170.1Cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heo, J. H.
Right arrow Articles by Nam, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heo, J. H.
Right arrow Articles by Nam, J. M.
Related Collections
Right arrow Acute Cerebral Infarction
Right arrow Thrombolysis

(Stroke. 2003;34:e48.)
© 2003 American Heart Association, Inc.


Research Reports

Increase in Plasma Matrix Metalloproteinase-9 in Acute Stroke Patients With Thrombolysis Failure

Ji Hoe Heo, MD, PhD; Seo Hyun Kim, MD; Kyung Yul Lee, MD; Eun Hee Kim, BS; Chong Kyu Chu, MD Jeong Mo Nam, PhD

From the Departments of Neurology and Preventive Medicine (J.M.N.), Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

Reprint requests to Ji Hoe Heo, MD, PhD, Department of Neurology, Yonsei University College of Medicine, Shinchon-dong 134, Seodaemoon-ku, Seoul, 120-752, Korea. E-mail jhheo{at}yumc.yonsei.ac.kr

Background and Purpose— Platelet-rich thrombi are resistant to thrombolytics. Matrix metalloproteinases (MMPs) may be involved in platelet aggregation and contribute to thrombolysis failure in stroke patients.

Methods— Plasma samples from 23 stroke patients who had received thrombolytics and from 47 healthy volunteers were examined for MMP-2 and MMP-9 by both enzyme-linked immunosorbent assays and zymography.

Results— The arteries were recanalized in 15 patients but not in the other 8. The MMP-9 plasma level was significantly higher in patients whose arteries were not recanalized.

Conclusions— MMP-9 may be associated with the formation of a thrombolytics-resistant thrombus.


Key Words: metalloproteinases • stroke, ischemic • thrombolytic therapy